Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients

By: Benzinga
Gilead Sciences (NASDAQ: GILD ) today announced results from two Phase 2 studies evaluating an all-oral treatment regimen of the investigational once-daily nucleotide analogue sofosbuvir plus ribavirin (RBV)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.